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Abstract
Background—Lymphovascular invasion (LVI) in colorectal cancer (CRC) is considered a strong
stage-independent prognostic factor and influences decisions regarding adjuvant chemotherapy in
patients with Stage II tumors. However, the degree of interobserver agreement among pathologists
for LVI in CRC is largely unknown. This study was undertaken to examine such interobserver
variability, and we hypothesized that the use of immunohistochemical markers for vascular and
lymphatic channels could improve interobserver agreement.
Design—Fifty cases of AJCC stage II moderately differentiated CRC from 1990 to 2005 from the
pathology archives were selected; mucinous, medullary, and other recognized special subtypes were
excluded. Fifty H&E slides (one from each case) were circulated to 6 GI pathologists, who
independently assessed small and large vessel invasion. No diagnostic guidelines were given to the
participating pathologists; each was instructed to apply the criteria for LVI that he or she used in
daily practice. Immunohistochemistry (IHC) for D2-40 and CD31 was performed on corresponding
paraffin blocks. The IHC slides were randomized, recirculated, and rescored for LVI. Results were
analyzed by kappa (κ)statistics, which correct for agreement by chance, and for percent agreement.
Results—The average κ values were determined for the H&E slides (large and small vessel), CD31
(small vessel), and D2-40 (small vessel) (Figure 1). Agreement was fair for H&E small vessel
invasion (κ = 0.28; 95%CI 0.22–0.34). The least agreement was seen in interpretation of H&E large
vessel invasion (κ = 0.18; 95%CI 0.11–0.26). Agreement was not improved by use of
immunohistochemical stains: CD31 (large vessel, κ = 0.42, 95%CI 0.20–0.63, small vessel, κ = 0.26,
95%CI 0.10–0.42) and D2-40 (κ = 0.32, 95%CI 0.21–0.42).
Conclusions—Interobserver variability in diagnosis of LVI was substantial on H&E slides and
did not improve upon use of IHC. Agreement in evaluation of large vessel invasion was only slightly
higher than would be seen by chance alone. This study highlights the need for criteria in evaluation
of lymphovascular invasion, as this assessment may impact patient prognosis and thus change the
course of clinical treatment.
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The histological identification of lymphovascular invasion (LVI) by tumor has long been
recognized as a potential prognostic indicator and predictor of patient outcome. Many studies
have investigated the presence of lymphovascular invasion in colorectal cancer and have
determined it to be a strong stage-independent prognostic marker (2,3,5,11–19,21). The
presence of lymphatic invasion in malignant polyps has been associated with an increased risk
of regional lymph node metastases (6,20,22), and tumor invasion of extramural veins has been
recognized as a risk factor for liver metastases (24). A College of American Pathologists (CAP)
Consensus Statement in 1999 reviewed the available literature and determined that “blood or
lymphatic vessel invasion” warranted placement in Category I as a factor “definitively proven
to be of prognostic import based on evidence from multiple statistically robust published trials
and generally used in patient management.”(5)
Given the importance of identifying LVI, it is crucial that pathologists agree on its identifying
features. However, there are several caveats to the available literature on lymphovascular
invasion. There is significant variability in recognition, diagnosis, and reporting of
lymphovascular invasion, as well as in processing of specimens (1,3,4). The number of sections
of tumor submitted in a resection specimen varies among institutions and may influence
detection of LVI. The number of levels cut from each block of tissue also varies among
practices. Pathologists may or may not choose to use ancillary stains such as elastin or
immunohistochemical markers of endothelium in order to aid in assessment of LVI. There is
also considerable interpretation variability among pathologists. The available published criteria
for the histological diagnosis of LVI on examination of the hematoxylin&eosin (H&E)-stained
slide include (5,24–28): presence of tumor cells within a vascular space; erythrocytes
surrounding the tumor cells; identification of endothelial cells lining the space; the presence
of an elastic lamina surrounding tumor; and attachment of tumor cells to the vascular wall.
Although criteria for LVI are recognized, issues in interpretation include the determination of
retraction artifact versus true vascular space; endothelial lining versus stromal fibroblasts; true
vascular invasion versus “floater” (knife carryover artifact); and the presence or absence of a
muscle wall. These difficulties in interpretation have been noted in the literature: a study of
venous invasion in malignant colorectal polyps showed that there is no difference in patient
survival and concluded that the criteria for diagnosis of vascular invasion is too “subjective”
to be of clinical importance (8)
In addition to issues of interpretation, there are variations in reporting of LVI and in study
methodology. Although the 1999 CAP Consensus Statement recommended reporting of both
small and large vessel tumor invasion as well as location of LVI (5), these recommendations
have not been universally adopted. Studies examining the link between LVI and patient
outcome are also inconsistent. Many retrospective studies extract the reporting of LVI from
the patient’s medical record, without review by a central pathologist for consistency. Others
make use of a single pathologist’s interpretation of LVI without taking into account potential
interobserver variability in diagnosis of LVI. And finally, most studies do not define the criteria
used to determine the presence or absence of LVI. The variability in sampling, interpreting,
diagnosing, reporting, and studying LVI leads to the obvious difficulty in determining its true
prognostic value.
The variation in diagnosis of lymphovascular invasion affects clinical assessment of prognosis
and may change the course of therapy for the patient (10,17,18,30). Interobserver studies
investigating pathology reporting of lymphovascular invasion in breast cancer have been
published (9,23). However, studies specifically addressing agreement in the diagnosis of LVI
in colorectal cancer, using both H&E-stained slides and immunohistochemistry have not been
undertaken previously. Our study aims to investigate interobserver agreement in the diagnosis
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tof LVI in colorectal carcinoma. The hypothesis is that the agreement among pathologists on
examination of the H&E slides is poor, but the use of ancillary immunohistochemical stains
CD31 and D2-40 increases both the diagnosis of LVI and the interobserver agreement, and
ultimately improves patient care.
MATERIALS AND METHODS
This study was reviewed and approved by the Vanderbilt Institutional Review Board. Fifty
cases of AJCC Stage II moderately-differentiated colorectal cancer diagnosed between the
years 1990 and 2005 and identified from the pathology archives were randomly selected for
study. Fifty cases were chosen in order to achieve reasonable statistical power, i.e., 80%, with
an interobserver study involving six pathologists. Mucinous and medullary carcinoma subtypes
were excluded in order to maintain some degree of uniformity in our sample population. Fifty
de-identified H&E slides (one from each case, representing a full-thickness section of tumor)
were circulated to six gastrointestinal pathologists in the United States. Each pathologist
independently assessed small and large vessel invasion, using his or her own criteria; no
diagnostic guidelines were provided.
Immunohistochemistry (IHC) for CD31 and D2-40 was then performed on the corresponding
paraffin blocks. The slides were deparaffinized in xylene and rehydrated. Antigen retrieval was
performed using a citrate buffer at pH 6.0 and pressure cooker for 15 minutes with a bench
cool down of 10 minutes. A hydrogen peroxide quench using 0.03% H2O2 with sodium azide
was performed for 5 minutes. A 20 minute incubation using serum-free Protein Block followed.
A 30 minute incubation using the primary antibodies (Dako CD31 monoclonal mouse anti-
human, CAT# M0823, at 1:200 dilution; Dako D2-40 monoclonal mouse anti-human, CAT#
M3619, at 1:100 dilution) was performed. Secondary detection consisted of a 30 minute
incubation using Dako Envision + HRP-labeled polymer and staining was visualized by 5
minute incubation with diaminobenzidine tetrahydrochloride (DAB). The slides were
counterstained with Mayer’s hematoxylin and coverslipped. Normal colon was used as a
control slide for each immunohistochemical stain.
The IHC slides were then de-identified, randomized, recirculated, and rescored for the presence
of small and large vessel invasion (CD31) and lymphatic invasion (D2-40). The H&E and IHC
scores were collected by a single pathologist (EIH). Results were analyzed by kappa statistics,
which correct for agreement by chance, and by percent agreement. Following analysis of data,
the participating pathologists submitted and discussed individual criteria used in the diagnosis
of LVI.
The statistical analyses of this study were focused on the estimation of the agreement rate and
Kappa Statistics among six GI pathologists. The estimation of the agreement rate was based
on the Binomial distribution. Kappa Statistics is a quality index, which compares the observed
agreement with agreement expected by chance. Agreement expected by chance is determined
by assuming each pathologist made their ratings randomly but with probabilities equal to the
overall proportions or marginal frequencies. The possible values of Kappa range from +1
(perfect agreement) via 0 (no agreement above that expected by chance) to −1 (complete
disagreement). The point estimates and the 95% confidence intervals of the agreement rate as
well as Kappa statistics were reported.
RESULTS
The overall average observed agreement amongst all six pathologists using H&E slides and
immunohistochemical stains was fair (agreement: 62.53; kappa (κ)= 0.24). One pathologist
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thad a noted tendency to diagnose positive lymphovascular invasion, while two pathologists
were very conservative in the diagnosis.
The average kappa values were determined separately for the H&E slides (large and small
vessel), CD31 (large and small vessel), and D2-40 (small vessel) (Figure 1). Interobserver
agreement was fair for H&E small vessel invasion (κ= 0.28; 95%CI 0.22–0.34). The least
agreement was seen in interpretation of H&E large vessel invasion (κ = 0.18; 95%CI 0.11–
0.26). Agreement was not improved by use of immunohistochemical stains: CD31 (large
vessel, κ = 0.42, 95%CI 0.20–0.63, small vessel, κ = 0.26, 95%CI 0.10–0.42) and D2-40 (κ =
0.32, 95%CI 0.21–0.42).
Values for observed agreement were similar to the kappa values above (Figure 2). However,
observed agreement was highest using H&E stains and CD31 immunohistochemistry to
evaluate large vessel invasion (H&E agreement = 76.80, 95%CI 65.24–88.36; CD31 agreement
= 89.49, 95%CI 84.45–94.13). The least agreement was seen in evaluation of small vessel
invasion on H&E stains (agreement = 66.40, 95%CI 62.95–69.85). Use of
immunohistochemistry did not significantly improve agreement of small vessel invasion:
CD31 (small vessel, agreement = 74.40, 95%CI 68.42–80.39) and D2-40 (agreement = 68.07,
95%CI 63.37–72.77).
DISCUSSION
Interobserver agreement in the diagnosis of LVI in Stage II colorectal carcinoma was poor on
H&E examination and did not improve with addition of immunohistochemical markers of
vascular and lymphatic endothelium. Notably, the interobserver agreement in evaluation of
large vessel invasion on H&E was only slightly higher than would be seen by chance alone.
Several hypotheses exist to explain the discrepancies in diagnosis. A logical explanation would
be that different criteria were applied by each pathologist. Following collection and analysis
of data, the participating pathologists submitted and discussed the individual criteria for LVI.
These criteria included: presence of tumor cells in a space lined by endothelial cells and/or
containing erythrocytes; endothelial cells present either completely surrounding the tumor, or
with only focal disruption; attachment of tumor cells to the vascular wall (Figure 3A); and
large vessel invasion defined by presence of a muscular wall, either adjacent to tumor or
disrupted by tumor. While individual criteria for small vessel invasion were concordant, the
interpretation of large vessel invasion varied among pathologists. Three pathologists required
only that tumor be present within or adjacent to the muscular wall (Figure 3B). The remaining
three pathologists required the presence of an elastic lamina surrounding the tumor focus or a
distinct disruption of the elastic lamina (Figure 3C).
This difference in evaluation of large vessel invasion does not fully explain the poor degree of
interobserver agreement. Another explanation for variation includes interpretation and
“threshold” for diagnosis. While one pathologist may be convinced that a small cluster of tumor
in a space with a few red blood cells equals small vessel invasion, another might interpret the
same findings as retraction artifact with carryover of erythrocytes. One pathologist may require
only one or two criteria to determine LVI (i.e. a space with a few endothelial cells), while
another requires the presence of most or all criteria. Another threshold for diagnosis includes
the amount of LVI present on the slide. If only a single suspicious focus is present, the
pathologist may be less likely to interpret the case as positive for LVI, as opposed to a case
with extensive vessel invasion present. Alternatively, in a case with obvious tumoral retraction
artifact, the pathologist may be less likely to interpret true LVI as positive.
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tAn additional consideration is to the attentiveness of each pathologist while examining the
slide. The participating pathologists undoubtedly spent a variable amount of time searching
each slide for single cell or small cluster LVI.
Immunohistochemical stains for CD31 and D2-40 were used to aid in identifying small and
large vessel invasion. CD31 is a marker of endothelial cells and is also designated “platelet
endothelial cell adhesion molecule-1” (PECAM-1). D2-40 is a relatively new
immunohistochemical stain that been demonstrated to label lymphatic endothelium but is
unreactive with vascular endothelium (7,29).
Upon the addition of the IHC slides, all participating pathologists identified more cases with
LVI than on initial H&E review. Interestingly, despite this increase, the interobserver
agreement was unimproved. This may be partially attributable to the randomization of the
slides; the de-identified slide numbers did not correspond between the H&E and IHC slides.
Also, the original H&E slide was not available for review after examination of the
corresponding IHC slide. It is possible that in practice, the addition of IHC would be helpful
in the examination of an area suspicious for LVI.
IHC for CD31 was somewhat challenging to interpret without the accompanying H&E slide.
CD31 will stain more than endothelial cells; reactivity will also be seen with macrophages,
platelets, lymphocytes, neutrophils, and fibroblasts. CD31 also reacts with lymphatics. There
was a moderate amount of background staining of stroma and inflammatory cells (Figure 4B).
The condensed stroma around a tumor focus may have been interpreted as endothelium by
some pathologists, and vice versa. Upon review by the participating pathologists, it was noted
that vessels present within the invasive tumor itself were interpreted as vascular invasion by
some participants (Figure 4C). The CD31 stain was confirmatory in several cases that were
highly suspicious for LVI on H&E examination (Figure 4A).
D2-40 was found to be a relatively clean and interpretable stain. There was some background
staining of stroma, especially myofibroblasts, and nerves that occasionally hindered
interpretation (Figure 4E), and no observed staining of blood vessel endothelium. The IHC
highlighted the abundant lymphatics present around the tumor, and served to identify single
cell (Figure 4C) and small cluster lymphatic invasion by tumor. Interobserver variation in this
case may be explained by threshold differences (one pathologist may be more willing to call
a single cell in a lymphatic “positive for invasion”). An example of a controversial D2-40
immunohistochemical image is presented in Figure 4F. There are also basic differences in
examination of the slide; invasion by a single cell is difficult to screen on low or medium power.
Formal interobserver studies of lymphovascular invasion in colorectal cancer have not been
previously undertaken. An interobserver study of lymphatic invasion in breast cancer has been
published with the conclusion that identification of lymphatic invasion is not a reliably
reproducible prognostic finding (31). Studies of vascular invasion in colorectal cancer have
found that the addition of an elastin stain may improve the diagnosis; however, formal
interobserver agreement studies were not performed (32–34).
The results of this study highlight the necessity for improvement in our criteria for diagnosis
of LVI and call into question all studies examining the association of LVI with patient outcome
and prediction of response to treatment. The quest to improve interobserver agreement is a
challenging one. The main barrier to improvement lies in the lack of a gold standard for LVI.
The presence of metastases to lymph nodes and distant organs proves that LVI has occurred,
but does not prove that a single focus on a single slide is necessary true LVI. The current
recommendations from the 1999 CAP Consensus Statement include the presence of tumor in
a vascular space lined by endothelium, attachment of tumor to the vascular wall, and presence
of an elastic lamina surrounding a tumor focus (for large vessel invasion). Strict adherence to
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tthese criteria, thus increasing the threshold for diagnosis of LVI, will improve agreement and
decrease the reported positive cases for LVI. This will not necessarily improve patient care, as
several studies have associated foci “suspicious for LVI” with increased risk for lymph node
metastases. In the future, improved histochemical and immunohistochemical stains identifying
blood vessels and lymphatics may also improve our diagnosis and agreement of LVI, and thus
improve patient care.
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tFigure 1. Interobserver kappa Values for Lymphovascular Invasion in Colorectal Cancer
[kappa graph with labels_Jan08]
Interobserver average kappa values show no significant improvement in agreement upon
addition of immunohistochemical stains.
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tFigure 2. Interobserver Agreement Values for Lymphovascular Invasion in Colorectal Cancer
[agreement graph with labels_Jan08]
Observed agreement values show the highest agreement using CD31 immunohistochemistry
to evaluate large vessel invasion.
Harris et al. Page 9









































































A: An example of positive small vessel invasion, diagnosed by all six participating pathologists
on H&E examination. H&E, 200×. B: Large vessel invasion by tumor. The tumor invades and
disrupts the muscular wall of the vessel. H&E, 100×. C: Large vessel invasion: the tumor
disrupts the muscular wall and elastic lamina of the obliterated blood vessel. H&E, 100×.
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A: An example of consensus agreement for small vessel invasion by tumor, as seen on CD31
immunohistochemical stain, 400×. B: Inflammatory cell staining in the background stroma
may hinder a diagnosis of single cell small vessel invasion. CD31 immunohistochemical stain,
400×. C: This cluster of tumor cells was called positive for small vessel invasion by some
participating pathologists due to the strong immunohistochemical staining for CD31; others
considered the case to be negative because the cluster was within the bulk of the tumor mass.
CD31 immunohistochemical stain, 400×. D: Single-cell lymphatic invasion by tumor
highlighted on D2-40 immunohistochemistry, 400×. E: Background stromal fibroblast staining
by D2-40 immunohistochemistry, 100×. F: A cluster of tumor cells is identified within a space
showing incomplete D2-40 immunoreactivity; the majority of participating pathologists
considered this to be positive lymphatic invasion. D2-40 immunohistochemistry, 400×.
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